Thioredoxin/Txnip: Redoxisome, as a Redox Switch for the Pathogenesis of Diseases by Eiji Yoshihara et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 09 January 2014
doi: 10.3389/fimmu.2013.00514
Thioredoxin/Txnip: redoxisome, as a redox switch for the
pathogenesis of diseases
EijiYoshihara1†, So Masaki 1†,Yoshiyuki Matsuo1, Zhe Chen1†, HaiTian2,3 and JunjiYodoi 1,2,3*
1 Institute for Virus Research, Kyoto University, Kyoto, Japan
2 Advanced Chemical Technology Center in Kyoto (ACT Kyoto), JBPA Research Institute, Kyoto, Japan
3 Redox Bio Science Inc., Kyoto, Japan
Edited by:
Pietro Ghezzi, Brighton and Sussex
Medical School, UK
Reviewed by:
Pietro Ghezzi, Brighton and Sussex
Medical School, UK
Anna Rubartelli, IRCCS AOU San
Martino IST, Italy
*Correspondence:
Junji Yodoi , Institute for Virus
Research, Kyoto University, Kyoto
606-8397, Japan
e-mail: yodoi@virus.kyoto-u.ac.jp
†Present address:
Eiji Yoshihara, Gene Expression
Laboratory, Salk Institute for
Biological Study, La Jolla, CA, USA;
So Masaki , Laboratory for Malignancy
Control Research, Medical Innovation
Center, Graduate School of Medicine,
Kyoto University, Kyoto, Japan;
Zhe Chen, Center for Genetics of
Host Defense, University of Texas
Southwestern Medical Center, Dallas,
TX, USA
During the past few decades, it has been widely recognized that Reduction-Oxidation
(redox) responses occurring at the intra- and extra-cellular levels are one of most important
biological phenomena and dysregulated redox responses are involved in the initiation and
progression of multiple diseases.Thioredoxin1 (Trx1) andThioredoxin2 (Trx2), mainly located
in the cytoplasm and mitochondria, respectively, are ubiquitously expressed in variety of
cells and control cellular reactive oxygen species by reducing the disulfides into thiol groups.
Thioredoxin interacting protein (Txnip/thioredoxin binding protein-2/vitamin D3 upregulated
protein) directly binds to Trx1 and Trx2 (Trx) and inhibit the reducing activity of Trx through
their disulfide exchange. Recent studies have revealed that Trx1 and Txnip are involved in
some critical redox-dependent signal pathways including NLRP-3 inflammasome activation
in a redox-dependent manner. Therefore, Trx/Txnip, a redox-sensitive signaling complex
is a regulator of cellular redox status and has emerged as a key component in the link
between redox regulation and the pathogenesis of diseases. Here, we review the novel
functional concept of the redox-related protein complex, named “Redoxisome,” consisting
of Trx/Txnip, as a critical regulator for intra- and extra-cellular redox signaling, involved in
the pathogenesis of various diseases such as cancer, autoimmune disease, and diabetes.
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INTRODUCTION
The thioredoxin (Trx) system, composed of NADPH, thioredoxin
reductase (TrxR), and Trx, is a key antioxidant system that protects
cells from oxidative stress through its disulfide reductase activ-
ity. Trx1 and Trx2 are mainly localized in the cytoplasm and the
mitochondria respectively, suggestive of their specific roles at dif-
ferent cellular compartments (Box 1). Trx are highly conserved
in many organisms ranging from bacterial organisms to plants
and mammals, indicating that the Trx system is a cellular sys-
tem, essential for cellular survival and function. Recent studies
have shown that an important Trx binding protein, thioredoxin
interacting protein [Txnip/thioredoxin binding protein-2 (TBP-
2)/vitamin D3 upregulated protein (VDUP1)] has the reciprocal
function with Trx in the pathogenesis of disease such as autoim-
mune disease, cancer, and diabetes (1–3). Decades of research have
implicated Trx/Txnip regulation as an attractive therapeutic tar-
get. Here we review the novel protein signaling complex we call
“Redoxisome” as a redox-related signal transducer to highlight the
novel therapeutic approach by Trx/Txnip.
THIOREDOXIN1 AND THIOREDOXIN2
In mammalian cells there are two isoforms of Trx called as Thiore-
doxin1 (Trx1) and Thioredoxin2 (Trx2) (7). Trx1 is mainly located
in cytosol but also translocate to the nucleus and can be secreted
from cells under certain circumstances [circulatory thioredoxin
function were reviewed by our recent paper (8)], whereas Trx2 is
located only in mitochondria. Trx1 is a 12-kDa ubiquitous protein
that has disulfide-reducing activity. Trx are characterized by the
presence of three conserved prolines, with one located between
the catalytic cysteine residues of the – Cys-Gly-Pro-Cys – motif.
Two cysteine residues (Cys-32 and -35) of the active site – Cys-Gly-
Pro-Cys – are responsible for this reducing activity. This proline
is the key residue that determines the reducing power of Trx and
replacing it by a serine or a threonine has a dramatic effect on
the redox and stability properties of the protein (9–13). Trx1 was
originally identified as a hydrogen donor for ribonucleotide reduc-
tase in Escherichia coli (14). We have identified human Trx1 as
an adult T cell leukemia-derived factor (ADF) from the super-
natant of human T-cell leukemia type-1 (HTLV-1) infected T cell
line, which was initially defined as autoimmune lymphokine and
IL-2 receptor-inducing factor (15). In line with its function to
respond to oxidative stresses, Trx1 expression is induced by vari-
ety of physiochemical stimuli, including virus infection, mitogen,
UV-irradiation, hydrogen peroxide, ischemia reperfusion, which
we have broadly reviewed (1, 3, 8, 16). The crystal structures of
Trx1 in both oxidized and reduced states have been resolved and
revealed that Trx1 has a basic Trx-fold (consisting of four β2-
strands surrounded by three α2-helices) with additional α2-helices
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Box 1 Localization of Trx andTxnip, predicted existence of redoxisome in nucleus, cytosol, mitochondria, cellular membrane, and
extra-cellular space.
It is well known that Trx1 is localized in the cytosol, plasma membrane (PM), and nucleus as well as the extra-cellular space. Since Trx2 is
localized in only mitochondria, the Trx/Txnip redoxisome system is mainly works as the Trx2/Txnip complex in mitochondria. It was found
that this complex only occurs under the oxidative stress since Txnip is shuttled into mitochondria under stress and remains in the nucleus
under the normal condition (4). Recently, it was found that Txnip is also located in PM (5). Poly-ADP-ribose polymerase 1 (Parp1) was found
to be a binding protein forTxnip in the nucleus and the inhibition of Parp1 increases PM associatedTxnip localization in human umbilical vein
endothelial cells (HUVECs), suggesting that the translocation of Txnip from the nucleus to the PM is exclusively related to Parp1 inhibition.
SinceTxnip and Parp1 are both regulated by changes in cellular redox state in HUVECs, this novel PM associatedTxnip could be associated
with Trx1 and form a redoxisome system in the PM. Nuclear transport protein, importin-α was identified as a binding protein of Txnip, and
the binding leads to the translocation ofTxnip from the cytosol to the nucleus (6). Although it is still unknown whetherTxnip is released into
the extra-cellular space like Trx1, further studies about the localization specific Trx/Txnip, redoxisome system could give us a novel insight
for a redox-dependent biological function in the cells.
and β2-strands at the N-terminus (10, 17). Natural metabolic or
endocrine substances including hemin, estrogen, prostaglandins,
sulforaphane, and cAMP can also induce the expression and secre-
tion of Trx1. A series of stress-responsive elements in the promoter
region have been identified, including the oxidative stress response
element (ORE), antioxidant responsive element (ARE), cAMP
responsive element (CRE), xenobiotics responsive element (XRE),
and Sp-1. Trx1 is also induced by fragrant unsaturated aldehydes
from edible plants, through their ARE in the promoter region,
meaning that Trx1 may be beneficial for protection against oxida-
tive stress-induced cellular damage (18). Trx1-knockout mice are
lethal due to early development and morphogenesis failure of the
mouse embryo (19), whereas Trx1-transgenic (Trx1 Tg) mice are
more resistant to oxidative stress with longer life span compared
with wild type mice (20). These results suggest that Trx1 is an
essential molecule for cellular and organismal survival. Decades of
research have shown that Trx1 binds and modulates together pro-
teins such as Nuclear Factor-κB (NF-κB), p53, hypoxia inducible
factor-1 (HIF-1), Forkhead box class O1 (Foxo1), glucocorticoid
receptor (GR), and Estrogen Receptor (ER) by a thiol-disulfide
exchange reaction (3, 21). Trx1 binding protein that we identi-
fied in 1999 and named TBP-2, now commonly called as Txnip
is a unique Trx binding protein that has a role as an endogenous
inhibitor of Trx, since Txnip binding to Trx inhibits. Their pro-
tein reducing activity and/or Trx expression (22). This finding
has implicated that redox-sensitive proteins and related cellular
processes such as metabolism, proliferation, and inflammation
could be regulated by Trx/Txnip signaling.
THIOREDOXIN INTERACTING PROTEIN (TBP-2/VDUP1)
Thioredoxin interacting protein (TBP-2/VDUP1) was originally
cloned as a vitamin D3 target gene in HL-60 cells (23) (named as
VDUP1). This molecule has emerged as a key component of cel-
lular redox regulation since it was identified as binding partner of
Trx and suggested to be an endogenous Trx inhibitor (22) (named
as TBP-2). It has been known that the two Txnip cysteins are
important for thioredoxin binding through a disulfide exchange
reaction between oxidized Txnip and reduced Trx (24). This clear
evidence suggests that the Trx-Txnip complex is important for
redox-dependent cell function. Interestingly, Txnip is a member of
theα-arrestin protein family (Arrdc1–5 and Txnip) containing two
characteristic arrestin-like domains with PxxP sequence, which is
a known binding motif for SH3-domains containing proteins, and
PPxY sequence that is know binding motifs for WW-domain (2,
24–27). Since Txnip has a specific arrestin-like domain, which is
responsible for protein–protein binding, many interacting protein
for Txnip have been identified such as importin-α, transcriptional
co-repressors SMRT-mSin3-HDAC (histone deacetylase), Jab1, E3
ubiquitinligase itch, Mybbp1a, and NOD-like receptor Protein-
3 (NLRP3) as well as Trx (6, 28–32). These finding raises the
possibility that Txnip may have a role for scaffolding in a signal-
ing complex. Interestingly, genetic mapping identified a nonsense
mutation in the Txnip gene as the cause for the phenotype in the
Hcb-19 mutant mouse, which resembles familial combined hyper-
lipidemia (FCHL) (named as Txnip) (33). The mutation causes
the truncation of Txnip in a critical region, which was reported
to mediate Txnip’s binding to Trx1. Moreover Hcb-19 mice have
decreased CO2 production but increased ketone body synthe-
sis, suggesting that altered redox status may have a role in lipid
metabolism such as citric-acid cycle and fatty acid utilization (34).
We reported that disruption of Txnip (Txnip KO) by gene
targeting in mice causes predisposition to death with severe bleed-
ing, hypoglycemia, hyperinsulinemia, and liver steatosis during
fasting (35). Txnip gene expression is induced in fasting, and
the key transcription regulator peroxisome proliferator activated
receptor-alpha (PPAR-α) and sterol response element binging pro-
tein (SREBP) signaling are dysregulated in the liver of Txnip
KO during the feeding-fasting nutritional transition (36). Txnip
expression is widely regulated by nutritional status, signal, and
enzyme such as feeding-fasting, obesity, high glucose, amino acids,
nuclear receptor signal (PPARs, VDR, GR), and AMPK (23, 26, 28,
36–41). These results clearly suggest that Txnip is an important
molecule that regulates glucose and lipid homeostasis.
A critical role of Trx and Txnip in inflammation, cancer
progression, and diabetes is mentioned in a later part of this review.
THIOREDOXIN1/TXNIP, REDOXISOME, A REDOX-RELATED
SIGNAL COMPLEX
The Trx system plays an important role in maintaining a reduced
environment in the cell. We first identified Txnip/TBP-2/VDUP1
as an endogenous Trx1 binding and inhibiting protein (22). Inter-
estingly, Txnip binds to reduced Trx1 but not to oxidized Trx1 nor
to mutant Trx1, in which two redox active cysteine residues are
substituted by serine (22). Since the disulfide exchange reaction
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between oxidized Txnip and reduced Trx1 [Txnip and Trxs form
a stable disulfide-linked complex (24)] is known as the essential
event for the interaction between Txnip and Trx1, two Txnip cys-
teines are important for Trx1 binding (Figure 1). These cysteines
are not conserved in the broader family of arrestin domain-
containing proteins, therefore, the Trx1 binding property of Txnip
FIGURE 1 |Trx/Txnip signaling complex as redoxisome. Txnip contains
an intramolecular disulfide band between Cys-63 and -247 that allows
efficient interaction with Trx. Txnip forms disulfide bond with reduced TRX
by disulfide exchange, making a stable Trx mixed disulfide.
is unique (24). Thus, the catalytic center of Trx1 seems to be impor-
tant for the interaction. This interaction is important for cellular
redox regulation since the protein reducing activity of Trx1 is
actually inhibited by Txnip interaction (22, 24). In COS-7 and
HEK293 cells transiently transfected with Txnip expression vec-
tor, decreased of insulin reducing activity of Trx1 and diminished
expression of Trx1 was observed (22). In addition, treatment of
HL-60 cells with 1α, 25-dihydroxyvitamin D3 caused an increase
in Txnip expression and down-regulation of the expression and
the reducing activity of Trx1. These results suggest that Txnip
serves as a negative regulator of the biological function and expres-
sion of Trx1 by direct interaction and provides insight into the
redox-dependent signal complex (Figure 1). We would like to
propose the concept of “Redoxisome” that the signaling com-
plex, composed with Trx and Txnip as a redox-dependent signal
complexes, “Redoxisome” since it seems this signal complex could
be key regulatory mechanism in multiple condition and diseases
(Figure 2).
THIOREDOXIN2/TXNIP, REDOXISOME IN MITOCHONDRIA
The Trx/Txnip, redoxisome system also exists in mitochondria
(42–44). The major difference between the cytosolic Trx system
and the mitochondrial Trx system is that cytosolic Trx system
consists of Trx1, TrxR, and Peroxiredoxin (Prx) while that of
mitochondria consists of Trx2, TrxR2, and Prx3 (45, 46). Interest-
ingly, Txnip interacts with both cytosolic Trx1 and mitochondrial
Trx2 (4, 47), meaning that the Trx/Txnip, redoxisome system
works in both cytosol and mitochondria. Txnip can translocate
to the mitochondria, where it binds to oxidized Trx2 leading to
FIGURE 2 | Beneficial effect ofTrx1/Txnip signaling for clinical aspect. The beneficial effect by increasing of Trx1 and decreasing of Txnip expression are
shown. Green box indicate the beneficial effect in diabetes while red box indicate the concern about adverse effect in cancer development by reduced Txnip
expression.
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mitochondrial dysfunction (4). Since Trx2 bind to Apoptosis sig-
nal regulating kinase 1 (Ask1), a major mitogen-activated protein
kinase kinase kinase (MAPKKK) and inhibits Ask1 phosphoryla-
tion and activation, increased binding of Txnip to Trx2 reduces
the interaction between Trx2 and Ask1 and induces Ask1 activa-
tion for apoptosis (4). It is also reported that Txnip translocation
increase reactive oxygen species (ROS) accumulation in mitochon-
dria and leads to activation of the NLRP3 inflammasome (47).
However the function of Trx2 in regulating the inflammasome has
not been studied to determine whether it is an essential component
of NLRP3 activation in mitochondria.
THIOREDOXIN1/TXNIP, REDOXISOME, CRITICAL FOR
PATHOGENESIS OF TYPE 1 AND 2 DIABETES
Diabetes is characterized by high blood glucose levels, as results of
insufficient insulin due to reduced insulin secretion and/or insulin
sensitivity for the body’s required. Type 1 Diabetes (T1DM) is an
autoimmune disease that results in β-cells destruction. It usu-
ally presents in childhood, accounts for 5–10% of all diabetes,
and is associated with the presence of islet-cell antibodies, and
patients require lifelong insulin treatment. While, Type 2 Diabetes
(T2DM), the most common form of the disease, is characterized by
defects in both insulin secretion from pancreaticβ-cells and insulin
sensitivity in peripheral tissues such as skeletal muscle, liver, and
fat. T2DM is influenced by life style factors such as age, pregnancy,
and obesity, but also has a strong genetic component (48). Despite
the differential mechanism for the pathogenesis of T1DM and
T2DM, oxidative stress is commonly related to the pathogenesis
of the disease (49). It has been known that low levels of cellular
ROS are required for cellular signaling, such as optimal tyro-
sine phosphorylation-dependent signaling in vitro (49–51), while
chronic excessive generation of ROS aggravate insulin sensitivity
in skeletal muscle and disrupt β-cell function and survival (52),
suggesting that an optimal balance of cellular redox regulation is
critical for the pathogenesis of both T1DM and T2DM.
Thioredoxin1-transgenic mice on a C57BL/6J background, in
which human Trx1 is systemically overexpressed under control
of the β-actin promoter, are more resistant to various oxidative
stresses than control mice (20, 53–57). Trx1 Tg mice have more
resistance to develop both T1DM and T2DM in mice (55–58).
In non-obese diabetic (NOD) mice (T1DM model) or strep-
tozocin (STZ) induced T1DM model mice, β-cell-specific over-
expression of Trx1 markedly reduces the incidence of diabetes
without improving insulin secretory capacity, insulin content, or
the development of insulitis compared with those of littermate
controls (55).
Recently it was reported that in an animal model of T2DM,
obese diabetic db/db mice,β-cell-specific Trx1 overexpression sup-
presses progressive β-cell failure (56). Trx1 Tg db/db mice exhibit
significantly lower blood glucose levels and higher plasma insulin
levels compared with littermate controls (56). These results sug-
gest that Trx1 has a protective effect on reducing oxidative stress
inducing failure in T1DM and T2DM.
The endogenous Trx1 inhibitor, Txnip, was implicated as a
redox rheostat to control Trx1 activity and expression. Recent
studies suggested that Txnip expression is increased in skeletal
muscle of human T2DM and impaired glucose tolerance (IGT)
patients (59, 60). It was also reported that a genetic variation of the
Txnip gene is associated with hypertriglyceridemia and increased
diastolic blood pressure (61). Interestingly, Txnip expression is
induced by high glucose conditions, while it is reduced by insulin
(59). We reported that Txnip is more abundantly expressed in
pancreatic islets, skeletal muscle, adipose, and kidney of leptin defi-
cient ob/ob mice (T2DM model) compared with WT control mice
and Txnip deletion in ob/ob mice (T2DM model) dramatically
improves insulin resistance in skeletal muscle and β-cell insulin
secretion function and survival (28). Piled evidence suggested that
Txnip induced β-cell apoptosis under various kinds of stresses
such as STZ treatment (T1DM model) (62, 63), high glucose (28,
29, 64, 65), ER-stress (66–68), dexamethasone/glucocorticoid (69),
and inflammation/cytokine (29, 62), while it has been reported
that Txnip aggravates hepatic glucose production (70) and insulin
sensitivity in skeletal muscle (28, 71) and adipose tissues (72, 73).
These evidences suggest that Trx1 and Txnip have an antagonistic
function in progression of both T1DM and T2DM.
THIOREDOXIN1/TXNIP, REDOXISOME, A NOVEL REGULATOR
OF NLRP3 INFLAMMASOME AND INFLAMMATION
Human Trx1 is originally identified as an ADF (15, 74). Numerous
evidences suggest that Trx1 is an anti-inflammatory molecule in
both an intracellular and extra-cellular (8, 75–79) environment.
Interestingly Trx is highly expressed in human T cell leukemia
virus type-1 (HTLV-1)-transformed cell lines (ATL model cell
line), whereas the Txnip expression is lost in HTLV-I-positive,
interleukin-2-independent T cell lines but not in HTLV-I-negative
T cell lines (37, 80, 81), suggesting a role for Trx1/Txnip in
virus infection, prevention, and inflammation. Indeed, recent
works revealed that Txnip has important role in inflamma-
tion in response to excessive nutrition, oxidative stress, and
lipopolysaccharide (LPS) stimulation (29, 66–68, 82–85).
Recent publications suggest a physical interaction between
Txnip and NLRP3, a key component of NLRP3 inflammasome
(29, 66, 67, 82, 83). The inflammasome is the multiprotein com-
plex that controls the activation of caspase-1 in the innate immune
system that result in maturation of IL-1β. ROS is the major activa-
tor of the NLRP3 inflammasome. The physical interaction between
Txnip and NLRP3 may explain the inflammasome activation in a
ROS-sensitive manner (29) especially in macrophages in pancre-
atic islets (29, 67). The study, performed by Zhou et al. suggested
that under the unstressed condition, Txnip is bound to Trx1 and
NLRP-3 inflammasome is in active because of an absence of Txnip
interaction with NLRP3, while under the oxidative stress con-
dition, ROS generation facilitates Trx1-Txnip dissociation, thus
increasing NLRP3-Txnip interaction. However there are some
conflicting reports. Although Koenen et al. demonstrate that
hyperglycemia activates caspase-1 and Txnip, glucose-induced
activation of Txnip mediates an increase of IL-1β mRNA and
intracellular pro-IL-1β rather than IL-1β processing (73). Further-
more, our collaborator Masters et al. and we found no significant
difference in IL-1β secretion in response to inflammasome activa-
tors in bone marrow derived macrophages of Txnip KO mice (86).
These evidences imply that the redox-dependent NLRP3 inflam-
masome activation is performed not only by Txnip-NLRP3 direct
interaction but also by other mechanisms regulated by Trx1/Txnip
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with other participants for redoxisome signaling. Thioredoxin
reductase (TrxR) might be involved in redox-sensitive inflam-
masome activation through Trx/Txnip, redoxisome signal since
it has reported that under the absence of TrxR condition, Trx1
is able to recycle substrates at the expense of an alternative elec-
tron donor that is required to be oxidized form of Trx1 (87). It is
possible there is an unknown potential redoxisome signal includ-
ing TrxR, Trx1, and Txnip that lead to the activation of NLRP3
inflammasome.
Although increased production of ROS is often though to be
implicated in the activation of inflammation, redox-related sig-
nal molecules are involved in NLRP3 inflammasome activation
in a ROS-independent manner. It has reported that cells from
patients with chronic granulomatous disease (CGD), character-
ized by an incapacity of phagocytosis to produce ROS due to a defi-
ciency in the NADPH oxidase system produce more inflammatory
cytokines including IL-1β (88). Since TrxR is the mediator of the
NADPH oxidase system, TrxR may link redox-related molecules
such as Trx1 and Txnip to NLRP3 inflammasome activation with-
out ROS signaling. Further studies addressing ROS-independent
activation of NLRP3 inflammasome will be required to under-
stand the contribution of Trx1/Txnip to NLRP3 inflammasome
activation.
Cigarette smoke-driven inflammatory airway disease such as
chronic obstructive pulmonary disease (COPD) is aggravated by
P2× 7/inflammasome pathway (89). We reported that Trx1 Tg
mice are resistant to COPD induced by cigarette smoke (76, 90,
91). It would be another interesting model for the redoxisome to
investigate whether the cigarette smoke-induced inflammation is
also regulated by the ratio of Trx1-Txnip interaction and NLRP3-
Txnip interaction. The association of Txnip with Trx1 and NLRP3
indicates that Txnip plays a major role in the convergence of mul-
tiple signaling pathways that contribute to oxidative stress-related
disorders.
Collectively, although Trx1/Txnip is likely involved in the acti-
vation of NLRP3 inflammasome, the mechanistic insight is still
unclear. Therefore the novel concept of redoxisome consisting of
Trx1/Txnip and other redox-related molecules could give us novel
insight for the currently unknown mechanism of NLRP3 inflam-
masome activation in ROS-dependent and-independent manner.
Future experiments will have to be performed to establish if the
Trx1/Txnip redoxisome system contributes as redox regulatory
system to NLRP3 inflammasome activation.
THIOREDOXIN1/TXNIP, REDOXISOME, CANCER
PROGRESSION, AND OTHER DISEASE
Txnip overexpression arrests the growth of cells at G0/G1 phase
(92), and induces apoptosis in response to various stresses (30,
38, 41, 64, 93). Txnip is reported to inhibit cell cycles by sta-
bilizing p27 via binding to Jab1 (31), and by repressing tran-
scriptional activities via interaction with HDAC1 (94). More-
over Txnip is down-regulated in various human cancer cells and
many reports have shown that the down-regulation of Txnip
contributes the malignancy of cancer (2). In HTLV-1-infected T
cells, the expression level of Txnip is associated with responsive-
ness to IL-2-dependent growth, and epigenetic silencing of Txnip
results in loss of responsiveness to IL-2 (81). In IL-2-independent
stage, Txnip silencing loses the sensitivity against glucocorticoid-
induced cell death (38). In in vivo studies, Txnip has been
shown to be a suppressor of the incidence and progression of
cancer. The Hcb-19 mice strain with a spontaneous mutation
of Txnip gene and Txnip KO mice show the higher incidence
of hepatocellular carcinoma (95, 96). Also the Txnip KO mice
show earlier onset of N -butyl-N -(4-hydroxybutyl) nitrosamine
(BBN)-induced bladder carcinoma (97). Moreover, in clinical
studies, Txnip expression levels decrease following the progres-
sion of cancer stages or malignancy in gastric cancer, melanoma,
pheochromocytoma, and bladder cancer (97, 98). These results
collectively support that Txnip contributes to controlling the
malignancy of cancer. It has been also reported that the deficiency
of Txnip promotes TNF-α-induced NF-κB activity, that Txnip
inhibits mTOR activity by binding Redd1 (99), and that Txnip
deficiency enhances the phosphorylation of Akt in response to
insulin (28, 72).
Txnip deficiency also enhances phosphorylation of signal
transducers. Regarding the relationship between Txnip and cell
signaling, phosphorylation of ERK is enhanced in Txnip KO mice
bladders during BBN-induced bladder carcinogenesis (97), and
TGF-β signaling is enhanced via Smad2 phosphorylation under
Txnip-KO or -knockdown condition (100). The loss of Txnip up-
regulates a variety of transcriptional activities for several stimuli or
ligands, so that deficiency of Txnip could contribute to integrate
excessive biological responses and signals for cell survival, malig-
nancy, and the tumorigenesis of cancer. Here, at the mention of
the correlation between Txnip and Trx1, many reports show that
Txnip interacts with Trx1. Overexpression of Txnip attenuates
the reducing activity, and inhibits transcription of Trx1 result-
ing in increased ROS, which triggers cell cycle arrest or apoptosis
(as referred above). The gene expression of Txnip vs. Trx1 shows
a reciprocal pattern under the stimulation of vitamin D3 (22),
PPAR-γ ligands (26), and suberoylanilide hydroxamic acid (HDAC
inhibitor) (92) (Table 1). In the EGF-induced ERK1/2 phospho-
rylation, Txnip, and Trx1 apparently show reciprocal functions. As
shown in several reports, Trx1 overexpression increases activation
of ERK1/2 (101, 102) as well as Txnip deficiency. Interestingly,
Txnip overexpression strongly reduced Trx1 expression and activ-
ity (22, 24, 103), while Txnip deletion has a minor effect of Trx1
expression and activity (104). In regards to TGF-β signaling, TGF-
β-induced transcriptional activation is independent of the protein
levels of Trx1 (100). These results give us the idea that the event
of redox-dependent interactions between Trx1 and Txnip, result-
ing in the timely attenuation or enhancement of the functions in
response to oxidative stresses, may be more biologically important.
Further investigation is required to determine whether chronic
oxidative stresses cause the inconsistent expression of Trx1 and
Txnip by some feedback pathways. Future studies must unveil
the physiological significance of the formation of the Trx1/Txnip
complex.
A PERSPECTIVE OF TRX/TXNIP OF CLINICAL WORK
The modulation of cellular redox regulation has emerged as a
potential clinical approach for cancer, autoimmune disease, and
diabetes. In this review, we proposed the Trx/Txnip signal com-
plex is important for redox regulation and related disorders. The
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Table 1 | Reciprocal function betweenTrx1 andTxnip.
Biological event (tissue/cell type) Trx Txnip Reference
β-cell apoptosis (islet β-cells) Protect Promote (28, 55–57, 62–65, 67, 68)
Gluconeogenesis (liver) No report Activate (70)
Glucose uptake (muscle, adipose) No report Suppress (28, 59, 71)
Insulin secretion (islet β-cells) No report Suppress (28, 36)
Insulin sensitivity (muscle, adipose) No report Suppress (28, 36, 59, 71, 72)
Inflammation (many cell types) Suppress Activate (29, 75, 78, 82, 84, 89)
NLRP3 inflammasome (macrophage, islet) Suppress Activate (29)
IL-2 responsive (T cell) Positive Negative (80, 81)
Neurodegenerative (brain) Protect Promote (53, 54, 93)
Adiposity/obesity (adipose, liver) No report Suppress (28, 33–36, 72)
ROS production (many cell types) Reduce Increase (20)
Cellular survival (many cell types) Promote Inhibit (19, 20, 42)
Metastasis (many cell types) No effect Suppress (99, 100)
Carcinoma (liver, bladder) No effect Suppress (94–97)
Cardiac hypertrophy (heart) Protect Promote (32)
function of Trx is to reduce cellular ROS and related stresses,
while Txnip has reciprocal function for Trx. This evidence gives
us a novel therapeutic approach to control Trx/Txnip. Since the
Trx/Txnip complex acts in various kinds of stresses, Trx/Txnip
may form a protein complex with other proteins. In this review,
we defined this redox-related signal complex as “Redoxisome” and
suggest it may be a promising therapeutic target. Many reports
suggest that increasing of Trx1 and decreasing of Txnip expres-
sion is beneficial for preventing hyper inflammation, neurode-
generation, and progression of diabetes, while there is the risk to
increase the chance of incidents for gastric (105–107), lung (108),
and liver (30, 95, 96) cancer, especially with reduction of Txnip
expression (Figure 2). To eliminate unwanted side effect such as
cancer development, the regulation of Trx1 and Txnip interaction
might be a more effective therapeutic approach than the regulating
their expression. Further elucidation of the mechanism for redox
regulation and pathogenesis of diseases by the Trx/Txnip, redox-
isome is required to understand how cells and the whole body
integrate the various redox signals under the multiple diseases
states and the future findings may give us promising redox reg-
ulated therapeutic approach by Trx/Txnip, redoxisome signaling
(Figure 2).
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